Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners CoTSE:3183 -0.39%62 EV-to-EBIT is 6.74 as of Aug. 29, 2026, which is 11% above its 10-year median of 6.07. GuruFocus rates TSE:3183 with a GF Score™ of 62/100 and a GF Value™ of 円1,501.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 97 Medical Distribution companies, WIN-Partners Co ranks better than 75.26% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
WIN-Partners Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円22,427 Mil.
WIN-Partners Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,916 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WIN-Partners Co EV-to-EBIT Related Terms
WIN-Partners Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, WIN-Partners Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's EV-to-EBIT falls into.
WIN-Partners Co's current Enterprise Value is 円19,650 Mil.
WIN-Partners Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,916 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WIN-Partners Co (TSE:3183) has a EV-to-EBIT of 6.74 as of Aug. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on WIN-Partners Co and its competitors. This is 11% above median its historical median of 6.07. Over the past decade, WIN-Partners Co's EV-to-EBIT has ranged from 2.17 to 14.52. According to the industry distribution chart, WIN-Partners Co ranks #24 out of 97 companies in the Medical Distribution industry, placing it in the top 24.7%.
Is WIN-Partners Co's EV-to-EBIT too high?
WIN-Partners Co's current EV-to-EBIT of 6.74 is 11% above median its 10-year median of 6.07. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 14.52. The Medical Distribution industry median EV-to-EBIT is 11.72. WIN-Partners Co's value of 6.74 is 42.5% below this industry median. Based on the distribution chart, WIN-Partners Co ranks #24 out of 97 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, WIN-Partners Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #24 out of 97 companies for EV-to-EBIT. This places WIN-Partners Co in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 11.72. WIN-Partners Co's value of 6.74 is 42.5% below this benchmark. Historically, WIN-Partners Co's own EV-to-EBIT has ranged from 2.17 to 14.52 over the past decade. While the company's 10-year median is 6.07 vs. the industry median of 11.72, WIN-Partners Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.72, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current EV-to-EBIT of 6.74 is 42.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current EV-to-EBIT is 6.74, which is 11% above median its own 10-year median of 6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,501.60, compared to a current price of 円1,268.00 — trading 15.6% below its estimated fair value. The current EV-to-EBIT is 6.74, which is 11% above median its 10-year median of 6.07 and 42.5% below the Medical Distribution industry median of 11.72. WIN-Partners Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current EV-to-EBIT is 6.74 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,268.00 is trading 15.6% below its estimated GF Value™ of 円1,501.60.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
EV-to-EBIT: 6.74 (11% above median its 10-year median of 6.07)
GF Value™: 円1,501.60 vs. price of 円1,268.00 (15.6% below fair value)
Industry Position: 42.5% below the Medical Distribution median (#24 of 97)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
62GF Score
Get the complete analysis for TSE:3183
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
